Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Reexamination Certificate
2006-09-05
2006-09-05
Stucker, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
C424S196110, C424S208100, C530S350000, C530S826000
Reexamination Certificate
active
07101552
ABSTRACT:
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.
REFERENCES:
patent: 5013548 (1991-05-01), Haynes et al.
patent: 5019387 (1991-05-01), Haynes et al.
patent: 5352576 (1994-10-01), Haynes et al.
patent: 5516632 (1996-05-01), Palker et al.
patent: 5518723 (1996-05-01), DeVico et al.
patent: 5843454 (1998-12-01), Devico et al.
patent: 5993819 (1999-11-01), Haynes et al.
patent: 2001/0036461 (2001-11-01), Haynes et al.
patent: 2003/0147888 (2003-08-01), Haynes et al.
patent: 2004/0001851 (2004-01-01), Haynes et al.
patent: 2004/0039172 (2004-02-01), Haynes et al.
patent: 2004/0086506 (2004-05-01), Haynes et al.
patent: 2004/0132010 (2004-07-01), Haynes et al.
patent: 2004/0197344 (2004-10-01), Haynes et al.
patent: WO 93/15750 (1993-08-01), None
patent: WO 95/29700 (1995-11-01), None
patent: WO 97/14436 (1997-04-01), None
patent: WO 01/56355 (2001-08-01), None
patent: WO 02/024149 (2002-03-01), None
patent: WO 03/039470 (2003-05-01), None
patent: WO 03/046137 (2003-06-01), None
patent: WO 2004009785 (2004-01-01), None
patent: WO 2004075850 (2004-09-01), None
patent: WO 2005016952 (2005-02-01), None
patent: WO 2005/028625 (2005-03-01), None
Stamatatos et al, “Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 Isolates”, AIDS Research and Human Retroviruses 16(10):981-994 (2000).
Hoffman et al, “Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein”, Proc. Natl. Acad. Sci. USA 96:6359-6364 (1999).
Golding et al, “Phorbol Ester-Induced Down Modulation of Tailless CD4 Receptors Requires Prior Binding of gp120 and Suggests a Role for Accessory Molecules”, Journal of Virology 69(10):6140-6148 (1995).
Kwong et al, “Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody”, Nature 393:648-659 (1998).
Wyatt et al, “Involvement of the V1/V2 Variable Loop Structure in the Exposure of Human Immunodeficiency Virus Type 1 gp120 Epitopes Induced by Receptor Binding”, Journal of Virology 69(9):5723-5733 (1995).
Trkoloa et al., “Human Monocional Antibody 2G12 Defines a Distinctive Neutralization Epitope on the gp 120 Glycoprotein of Human Immunodeficiency Virus Type1”, Journal of Virology 70(2):1100-1108 (1996).
Mo et al, “Human Immunodeficiency Virus Type 1 Mutants That Escape Neutralization by Human Monocional Antibody IgG1b12”, Journal of Virology 71(9):6869-6874 (1997).
Ye et al., “Association of Structural Changes in the V2 and V3 Loops of the gp 120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged in Vivo”, Journal of Virology 74(24):1955-11962 (2000).
Fouts et al, “Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope Glycoprotein Complex,”, Journal of Virology 71(4):2779-2785 (1997).
Sullivan et al, “CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization”, Journal of Virology 72(6):4694-4703 (1998).
Moore et al, “Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies”, Journal of Virology 68(12):8350-8364 (1994) -Abstract.
Jiang et al, “A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein”, Journal of Virology 72(12);10213-10217 (1998).
Rimsky et al, “Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides”, Journal of Virology 72(2):986-993 (1998).
Earl et al, “Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140”, Journal of Virology 75(2):645-653 (2001).
Collman et al, “An infectious molecular clone of an unusual macrophage-trophic and highly cytopathic strain of human immunodeficiency virus type 1”, Journal of Virology 66(12):7517-7521 (1992) -Abstract.
Munster et al, “A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1”, Journal of Virology 67(11):6642-6647 (1993) -Abstract.
Cormier et al, “Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120”, PNAS 97(11):5762-5767 (2000).
Hoffman et al, “A Biosensor assay for studying ligand-membrane receptor interactions: Binding of antibodies and HIV-1 Env to chemokine receptors”, PNAS 97(21):11215-11220 (2000).
Myszka et al, “Energetics of the HIV gp120-CD4 binding reaction”, PNS 97(16):9026-9031 (2000).
Roben et al, “Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1”, Journal of Virology 68(8):4821-4828 (1994) -Abstract.
Munster et al, “Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS”, Journal of Virology 68(6):4031-4034 (1994) -Abstract.
Earl et al, “Native oligomeric human immunodeficiency virust type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities”, Journal of Virology 68(5):3015-3026 (1994) -Abstract.
Furata et al, “Capture of an early fusion-active conformation of HIV-1 gp41”, Nature Struct. Biol. 5:276 (1998).
LaCasse et al, “Fusion-Competent Vaccines” Broad Neutralization of Primary Isolates of HIV , Science 283:357 (1997).
Boots et al, “Anti-Human Immunodeficiency Virus Type 1 Human Monoclonal Antibodies that Bind Discontinous Eptitopes in the Viral Glycoproteins Can Identify Mimotopes from Recombinant Phage Peptide Display Libraries”, AIDS Research and Human Retroviruses 13(18):1549-1559 (1997).
Bieniasz et al, “HIV-1-induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR-5 co-receptor”, The EMBO Journal 16(10):2599-2609 (1997).
Wild et al, “Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex”, Proc. Natl. Acad. Sci. USA 91:12676-12680 (1994).
Collman et al, “An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1”, Journal of Virology 66(12):7517-7521 (1992).
Alam et al, “T-cell-receptor affinity and thymocyte positive selection”, Letters to Nature 381:616-620 (1996).
O'Shannessy et al, “Immunization Chemistries Suitable for Use in the BIAcore Surface Plasmon Resonance Detector”, Analytical Biochemistry 205:132-136 (1992).
Mascola et al, “Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type I”, J, Infect. Dis. 173:340-348 (1996).
Rizzuto et al, “A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding”, Science 280:1949-1953 (1998).
Wyatt et al, “Involvement of the V1/V2 Variable Loop Structure in the Exposure of Human Immunodeficiency Virus Type 1 gp120 Epitopes Induced by Receptor Binding”, Journal of Virology 69(9):5723-5733 (1995).
Robertson et al, Recombination in AIDs Viruses, J. Mol. Evol.
Alam Munir
Haynes Barton F.
Liao Hua-Xin
Patel Dhavalkumar D.
Duke University
Nixon & Vanderhye P.C.
Stucker Jeffrey
LandOfFree
Immunogen comprising an HIV envelope protein, a ligand and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogen comprising an HIV envelope protein, a ligand and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogen comprising an HIV envelope protein, a ligand and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3542032